Results 181 to 190 of about 204,284 (265)

Hydroxyurea (hydroxycarbamide) use in adults with haemoglobin SC disease: A real‐world study in Quebec

British Journal of Haematology, Volume 209, Issue 3, Page 1291-1300, September 2026.
Summary Haemoglobin SC (HbSC) disease is the second most prevalent form of sickle cell disease, but evidence for hydroxyurea (hydroxycarbamide; HU) to prevent pain episodes was limited until the prospective identification of variables as outcomes for treatment (PIVOT) trial.
Alice Girard, Laurianne Charette, Mélissa Haouchine, Laurence Bozec, Mohamed Zakaria Bachir Bouyadjera, Mariane Poitras, Vincent‐Thierry Taillefer, Chloé Trudeau, Yves Pastore, Nathalie Letarte, Stéphanie Forté   +10 more
wiley   +1 more source

Clinical Characteristics of Sickle Cell Disease Patients with Leg Ulcer in Murtala Muhammad Specialist Hospital, Kano, Nigeria. [PDF]

Niger Med J
Borodo AM, Ibrahim UM, Ibrahim H.
europepmc   +1 more source

Hydroxyurea (hydroxycarbamide) in haemoglobin SC disease: Moving from therapeutic hesitation to evidence‐guided care

British Journal of Haematology, Volume 209, Issue 3, Page 1428-1430, September 2026.
Girard et al. report a retrospective, single‐centre, real‐world study evaluating hydroxyurea (hydroxycarbamide) use in adults with haemoglobin SC disease in Quebec. Hydroxyurea was associated with reduced vaso‐occlusive crisis composite events, mostly mild adverse events and no observed hyperviscosity‐related complications, while highlighting adherence
Tahereh Setayesh
wiley   +1 more source

A New Fetal Hemoglobin-Related Phenotype in Sickle Cell Anemia. [PDF]

Am J Hematol
Steinberg MH, Rees DC.
europepmc   +1 more source

The role of protein arginine methyltransferases in sickle cell‐mediated neurovascular impairments in mice

British Journal of Pharmacology, Volume 183, Issue 18, Page 5586-5601, September 2026.
Background and Purpose Sickle cell disease (SCD) is a hereditary blood disorder caused by mutation of β‐globin. In SCD, haemoglobin polymerization causes red blood cells to assume a rigid sickle‐shape leading to neurovascular alterations, including development of vascular dementia – characterized by cognitive impairment and reduced cerebral perfusion ...
Julia Zaccarelli‐Magalhães, Mariana Sayuri Berto Udo, Drew James Smith, Julia Langman, Luiz Henrique Matuguma, Guilherme Nagamine Gomes, Peter Rodriguez, Ammar Husan, Quanguang Zhang, Christopher G. Kevil, Cristiane Teresinha Citadin, Hung Wen Lin   +11 more
wiley   +1 more source

Uganda's Mandatory Newborn Sickle Cell Disease Screening Programme: Translating a Decade of Evidence into Differentiated Implementation. [PDF]

Pediatric Health Med Ther
Jonani B, Nakawuka B, Ssebunya E, Kwizera R, Bongomin F, Mboowa G.   +5 more
europepmc   +1 more source

The Influence of Fetal Hemoglobin on Hematological Parameters and Clinical Severity in Patients with Homozygous Sickle Cell Disease. [PDF]

Niger Med J
Talhar SS, Patil BU, Das DK, Ambulkar P, Waghmare JE, Jain J, Jain M, Gangane NM.   +7 more
europepmc   +1 more source

βT87Q-Globin Gene Therapy Reduces Sickle Hemoglobin Production, Allowing for <i>Ex Vivo</i> Anti-sickling Activity in Human Erythroid Cells. [PDF]

Mol Ther Methods Clin Dev, 2020
Demirci S, Gudmundsdottir B, Li Q, Haro-Mora JJ, Nassehi T, Drysdale C, Yapundich M, Gamer J, Seifuddin F, Tisdale JF, Uchida N.   +10 more
europepmc   +1 more source

Retinal Challenges in Sickle Cell Patients-Present and Future: A Systematic Review. [PDF]

Bioengineering (Basel)
Motulsky E, El Bachti A.
europepmc   +1 more source

Vitamin D Deficiency and Its Hematological Correlates in Patients with Sickle Cell Disease at a Ugandan Clinic. [PDF]

J Blood Med
Salamu G, John EA, Wagubi R, Muwanguzi E, Bagenda CN, Okongo B.   +5 more
europepmc   +1 more source